Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jan;35 Suppl 1(Suppl 1):10-4.
doi: 10.1002/clc.20989.

Can we predict outcomes in atrial fibrillation?

Affiliations
Review

Can we predict outcomes in atrial fibrillation?

Nihar R Desai et al. Clin Cardiol. 2012 Jan.

Abstract

Atrial fibrillation (AF) is the most common arrhythmia encountered by generalists and cardiologists alike. Much of the attendant morbidity from AF arises from systemic embolic complications which are effectively reduced with utilization of anti-platelet and/or anticoagulant therapy. The systemic embolic complications of AF and the medical therapy to attenuate these risks are very well established. Through the course of this review, we aim to highlight the complex relationship between AF and other, "non-embolic" outcomes. The presence of AF has been demonstrated to be associated with a 1.5 to 2-fold increase in mortality across numerous observational cohorts. Still further, AF frequently coexists with heart failure, whether as a causative factor or a consequence of underlying structural heart disease or neurohumoral derangement, where its presence is associated with worse clinical outcomes. Whether AF is an independent risk factor for acute coronary syndromes (ACS) remains controversial, though its occurrence in patients with ACS has been shown to be associated with adverse outcomes both in observational cohorts as well as clinical trial populations. Individuals with AF have a 1.5 to 3-fold increase in the rate of hospitalization and are at elevated risk for other arrhythmic disorders including both bradyarrhythmias as well as tachyarrhythmias. AF leads to considerable morbidity and mortality for patients and exacts a tremendous financial toll on the healthcare system-estimated to range from $6.0 to $26.0 billion. Given the current demographic transition in developed countries, the prevalence of AF will continue to increase and the need for refined approaches to risk stratification and pharmacotherapeutic interventions to attenuate the burden on patients will only become more important.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The relationship between atrial fibrillation with other adverse outcomes, including mortality, heart failure, acute coronary syndrome, other arrhythmias, and hospitalizations. The direction and size of the arrows is meant to convey the directional relationship and strength of association.

References

    1. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 Through 1999. Circulation. 2003;108:711–716. - PubMed
    1. Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4:313–320. - PubMed
    1. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98:946–952. - PubMed
    1. Stewart S. A population‐based study of the long‐term risks associated with atrial fibrillation: 20‐year follow‐up of the Renfrew/ Paisley study. Am J Med. 2002;113:359–364. - PubMed
    1. Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new‐onset atrial fibrillation. JAMA. 2011;305:2080–2087. - PMC - PubMed

MeSH terms